» Articles » PMID: 31808908

How We Perform Haploidentical Stem Cell Transplantation with Posttransplant Cyclophosphamide

Overview
Specialty Hematology
Date 2019 Dec 7
PMID 31808908
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

HLA-haploidentical hematopoietic stem cell transplantation is now one of the most commonly employed alternative donor techniques, with most centers applying T-cell-replete strategies such as that developed by the Baltimore group using high-dose posttransplant cyclophosphamide. HLA-haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide is associated with low rates of severe graft-versus-host disease and nonrelapse mortality and does not require graft manipulation or storage, which results in a low graft acquisition cost. Its remarkable safety when used with reduced-intensity conditioning has been demonstrated in patients up to 75 years old with outcomes similar to those of patients in their 50s. Several large, registry-based retrospective studies have confirmed the efficacy of HLA-haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide, achieving results comparable to those of HLA-matched hematopoietic stem cell transplantation. In this article, we describe our approach to this rapidly available and clinically simple platform and address some of the key clinical questions associated with its use.

Citing Articles

Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation.

Fuji S, Nakamae H, Sugita J, Najima Y, Konishi T, Tanaka T Bone Marrow Transplant. 2024; 59(11):1628-1630.

PMID: 39187600 DOI: 10.1038/s41409-024-02405-0.


The effect of oral nutrition supplement (ONS) on the nutritional and clinical status of patients undergoing autologous hematopoietic stem cell transplantation: study protocol for a randomized controlled clinical trial.

Habibi S, Ghoreishy S, Imani H, Barkhordar M, Vaezi M, Sadeghi E BMC Nutr. 2024; 10(1):83.

PMID: 38858716 PMC: 11163691. DOI: 10.1186/s40795-024-00893-3.


Post-transplantation cyclophosphamide is associated with increased bacterial infections.

Ustun C, Chen M, Kim S, Auletta J, Batista M, Battiwalla M Bone Marrow Transplant. 2023; 59(1):76-84.

PMID: 37903992 PMC: 11164622. DOI: 10.1038/s41409-023-02131-z.


Existence of HLA-Mismatched Unrelated Donors Closes the Gap in Donor Availability Regardless of Recipient Ancestry.

Chowdhury A, Maiers M, Spellman S, Deshpande T, Bolon Y, Devine S Transplant Cell Ther. 2023; 29(11):686.e1-686.e8.

PMID: 37586457 PMC: 10840626. DOI: 10.1016/j.jtct.2023.08.014.


Differential protein expression in endothelial cells exposed to serum from patients with acute graft-vs-host disease, depending on steroid response.

Martinez-Sanchez J, Palomo M, Pedraza A, Moreno-Castano A, Torramade-Moix S, Rovira M J Cell Mol Med. 2023; 27(9):1227-1238.

PMID: 37016544 PMC: 10148062. DOI: 10.1111/jcmm.17712.


References
1.
Ciurea S, de Lima M, Cano P, Korbling M, Giralt S, Shpall E . High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009; 88(8):1019-24. PMC: 4324621. DOI: 10.1097/TP.0b013e3181b9d710. View

2.
Kollman C, HOWE C, Anasetti C, Antin J, Davies S, Filipovich A . Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001; 98(7):2043-51. DOI: 10.1182/blood.v98.7.2043. View

3.
McCurdy S, Kanakry J, Showel M, Tsai H, Bolanos-Meade J, Rosner G . Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015; 125(19):3024-31. PMC: 4424420. DOI: 10.1182/blood-2015-01-623991. View

4.
Kanakry C, Fuchs E, Luznik L . Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016; 13(2):132. DOI: 10.1038/nrclinonc.2015.234. View

5.
Luznik L, ODonnell P, Symons H, Chen A, Leffell M, Zahurak M . HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14(6):641-50. PMC: 2633246. DOI: 10.1016/j.bbmt.2008.03.005. View